SCHEMBL17071972

SCHEMBL17071972

CC(=O)c1cc(F)ccc1-c1noc(C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.42
HCRTR2 O43614 3/20 0.42
TRPM8 Q7Z2W7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PLK1 P53350 1/20 0.40
RAB9A P51151 3/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
NPC1 O15118 2/20 0.39
OPRK1 P41145 5/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18594642 0.89 HCRTR1 (0.42) HCRTR1HCRTR2TRPM8L3MBTL1PLK1
SCHEMBL17723708 0.89 NPC1 (0.48) HCRTR1HCRTR2TRPM8L3MBTL1PLK1
SCHEMBL17069774 0.85 HDAC4 (0.41) HCRTR1HCRTR2TRPM8L3MBTL1PLK1
SCHEMBL18594628 0.81 HDAC4 (0.39) HCRTR1HCRTR2TRPM8PLK1OPRK1
SCHEMBL20911215 0.80 NPC1 (0.48) HCRTR1HCRTR2TRPM8L3MBTL1PLK1
SCHEMBL17071980 0.79 RAB9A (0.49) HCRTR1HCRTR2L3MBTL1PLK1RAB9A
SCHEMBL14363635 0.79 L3MBTL1 (0.47) TRPM8L3MBTL1RAB9ATSHRNPC1
SCHEMBL17069771 0.78 HCRTR1 (0.41) HCRTR1HCRTR2TRPM8L3MBTL1PLK1
SCHEMBL17071987 0.77 KMT2A (0.44) HCRTR1HCRTR2TSHRHDAC4HDAC1
SCHEMBL17071983 0.77 HCRTR1 (0.40) HCRTR1HCRTR2TRPM8L3MBTL1PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9586950-B2 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-03-07 US disclosed
US-20160304490-A1 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-10-20 US disclosed
US-20150252033-A1 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252033-A1 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NTSR2 HCRTR1 2/4885HCRTR2 1/4885TRPM8 710/4885
US-20160304490-A1 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY4R HCRTR1 2/4885HCRTR2 1/4885TRPM8 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.